Lomexin 2% Spray 30ml

NAME:
LOMEXIN

PHARMACOTHERAPEUTIC CATEGORY:
Topical antifungals.

ACTIVE PRINCIPLES:
Fenticonazole nitrate.

EXCIPIENTS:
2% cream: propylene glycol; hydrogenated lanolin; r refined almond oil; polyglycol ester of fatty acids; cetyl alcohol; glice ril monostearate; sodium edetate; purified water.
Skin spray, 2% solution: alcohol; propylene glycol; purified water.
2% cutaneous solution: alcohol; hydroxypropylcellulose; purified water; propylene glycol.
Skin powder 1%: colloidal hydrated silica; zinc oxide; talc.
Skin powder 2%: colloidal hydrated silica; zinc oxide; talc.

INDICATIONS:
2% cream, skin spray, 2% solution, 2% skin solution, 1% and 2% skin powder: dermatomycosis due to dermatophytes (Trichophyton, Microsporu m, Epidermophyton) with different localization: tinea capitis, tinea corp oris, tinea cruris, tinea pedis (athlete's foot), tinea manuum, tinea faciei, tinea barbae, tinea unguium; skin candidiasis (intertrig o, perleche, facial candidiasis, "diaper", perineal and scrotal candidiasis); balanitis, balanoposthitis; onychia and paronychia; pityrias is versicolor (from Pityrosporum orbiculare and P.
Oval); otomycosis (from C andida or from molds); only if there are no lesions of the eardrum; you were trash; mycosis with bacterial superinfections (from Gram positive bacteria).

CONTRAINDICATIONS / SECONDAR EFFECT:
Hypersensitivity to the active substance or to any of the excipients listed; pregnancy.

DOSAGE:
The product should be applied 1-2 times a day, according to medical opinion, after washing and drying the injured part, using the formulation suitable for the location of the lesion.
Cream 2%: it is indicated for the treatment of hairless skin, skin folds and mucus; it is applied by rubbing lightly.
It is preferably used for dry mycoses: pityriasis versicolor, erythrasma, onychomycosis (in onychomycosis the cream should be applied with an occlusive bandage); the cream is suitable for use in male genital mycosis.
Skin spray, 2% solution and 2% skin solution: they are indicated for localizations on the scalp and for skin areas covered with hair.
Furthermore, the skin spray solution is easy and convenient to use for extended mycos and areas that are difficult to reach.
Skin powder 1% and 2%: it is used for athlete's foot and in general for intertriginous areas and for wet lesions, both as a single treatment and as a complement to the cream.
In foot infections it is advisable to sprinkle the inside of socks and shoes with the drug powder.
The drug 1% cutaneous powder is indicated for the prophylaxis of r einfections.
In athlete's foot and onychomycosis, in order to avoid reinfections, it is advisable to continue the above treatment for another one or two weeks after the disappearance of the manifestations.
The product is not greasy, does not stain and is easily removable with water.

STORAGE:
None.

WARNINGS:
At the time of application on the lesion, a modest burning sensation may be found which disappears rapidly.
The use, especially if prolonged, of products for topical use, can give rise to sensitization phenomena.
In this case, stop the treatment and consult your doctor to institute suitable therapy.
2% cream, cutan eo spray, 2% solution, 2% cutaneous solution contain propylene glycol.
They can cause skin irritation.
The 2% cream contains alcohol.
It can cause local skin reactions (eg.
contact dermatitis); contains hydrogenated lanolin.
It can cause local skin reactions (eg.
contact dermatitis).

INTERACTIONS:
None known.

SIDE EFFECTS:
When used as recommended, Lomexin is only poorly absorbed and no systemic side effects are expected.
Prolonged use of topical products can cause sensitization phenomena.
Undesirable effects are listed below, listed by MedDRA system organ class and frequency: very common (> = 1/10); common (> = 1/100, <1/10); not common (> = 1 / 1,000, <1/100); rare (> = 1 / 10,000, <1 / 1,000); very rare (<1/10.
000); not known.
Skin and subcutaneous tissue disorders.
Very rare: erythema, pruritus, rash, erythematous rash, skin irritation, skin burning sensation.
The reporting of suspected adverse reactions that occur after the authorization of the medicine is important, as it allows continuous monitoring of the benefit / risk ratio of the medicine.

PREGNANCY AND BREASTFEEDING:
Although the percutaneous absorption of fenticonazole is rather poor, it is recommended not to use the drug during pregnancy.